Its role in the acute and chronic post-stroke phase has been corroborated in preclinical stroke models, where inhibition or genetic deletion of C3 was associated with reduced infarct volumes and improved neurological outcomes (Mocco et al. 2006; Stokowska et al. 2023). Here, C3 is linked to stroke disorder.